Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

Jacob Edward Till

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2824-1282; OpenAlex author ID A5059407389. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 10

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor … Co-author DOI 10.1158/1078-0432.ccr-25-3297↗
  3. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  4. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  5. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  6. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. First author DOI 10.1200/po.22.00060↗
  7. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.28127↗
  8. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  9. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.28099↗
  10. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Co-author DOI 10.1158/1078-0432.ccr-19-3313↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erica L. Carpenter · 10 shared papers, 2020–2026 · strength 1.45
  2. Mark H. O’Hara · 9 shared papers, 2020–2026 · strength 1.18
  3. Kim A. Reiss · 5 shared papers, 2021–2024 · strength 0.66
  4. Phyllis A. Gimotty · 3 shared papers, 2021–2026 · strength 0.53
  5. Kenneth Zaret · 3 shared papers, 2021–2026 · strength 0.53
  6. Peter James O'Dwyer · 4 shared papers, 2021–2024 · strength 0.51
  7. Thomas Benjamin Karasic · 3 shared papers, 2022–2024 · strength 0.41
  8. Bryson W. Katona · 3 shared papers, 2020–2022 · strength 0.34
  9. Samuele Cannas · 2 shared papers, 2024–2026 · strength 0.34
  10. Chen Yuan · 2 shared papers, 2024–2026 · strength 0.34
  11. Qiao-Li Wang Wang · 2 shared papers, 2024–2026 · strength 0.34
  12. Brian Matthew Wolpin · 2 shared papers, 2024–2026 · strength 0.34
  13. Jonathan Andrew Nowak · 2 shared papers, 2024–2026 · strength 0.34
  14. Charles M. Vollmer · 2 shared papers, 2020–2026 · strength 0.29
  15. Brianna M. Krusen · 1 shared paper, 2026 · strength 0.28
  16. Ann L. Oberg · 1 shared paper, 2026 · strength 0.28
  17. Shounak Majumder · 1 shared paper, 2026 · strength 0.28
  18. Jennifer Rachel Eads · 2 shared papers, 2022–2024 · strength 0.25
  19. Shirsa Udgata · 2 shared papers, 2021–2022 · strength 0.25
  20. Zev A. Wainberg · 2 shared papers, 2021–2024 · strength 0.22
  21. Andrew H. Ko · 2 shared papers, 2021–2024 · strength 0.22
  22. Robert A. Wolff · 2 shared papers, 2021–2024 · strength 0.22
  23. Eileen Mary O'Reilly · 2 shared papers, 2021–2024 · strength 0.22
  24. Robert H. Vonderheide · 2 shared papers, 2021–2024 · strength 0.22
  25. George Albert Fisher · 2 shared papers, 2021–2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.